Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
With many hepatitis C treatments on the market today, patients may ask which hepatitis C treatment is right for me? What’s the difference?
The first meta-analysis to examine hep C treatment outcomes in seniors versus non-seniors found that cure rates are comparable.
A study conducted in Australia treated people attending a syringe services program.
What’s more, such treatment is linked to remission of non–Hodgkin lymphoma.
A recent study of Dutch clinicians found that they generally did a good job of preventing drug-drug interactions.
These include a low CD4 count, having cirrhosis and taking certain hep C drug regimens.
The Phase IIb trial investigated the safety and efficacy of the JNJ-4178 regimen, which includes odalasvir, AL-335 and Olysio.
Those with stage 3 CKD saw their kidney function improve after treatment with various combo regimens, including Harvoni.
Researchers identified this association after looking at real-world data on a large group of German individuals with HIV and hep C.
A promising new regimen that will address unmet needs for this population is poised for FDA approval.
Those who beat hep C also reduced their insulin use.
The joint venture between the two companies will push the three-drug Olysio/odalasvir/AL-335 into further development.
FDA warns of risk of hepatitis B virus reactivation in patients coinfected with hepatitis C virus and hepatitis B virus.
An experimental hepatitis C virus (HCV) treatment regimen given for just six or eight weeks has shown promise in a mid-stage trial.
Gary Nash raises hepatitis C virus awareness by tackling TV’s toughest obstacle course.
Researchers have developed a mathematical model that can help determine if individuals can stop hepatitis C treatment early.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.